Efficacy and safety of abrocitinib monotherapy in adolescent…
Emerging
0
Citations0
Refs2023
Year
Search Works
Work Details
- DOI 10.6084/m9.figshare.22715514
- OpenAlex ID W6939636458
- Type Article
- Language EN
- Published 28 Apr 2023
- Source Figshare
- Publisher Figshare (United Kingdom)
- Added 10 Oct 2025
- Updated 14 Oct 2026
External Links
MENU
0
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial
Article 2023 EN Green
Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response. To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to treatment reintroduction after flare in adolescent and adult participants in JADE REGIMEN (NCT03627767). Adolescents (12–17 years) and adults with moderate-to-severe AD responding t…
0
Citations
0
References
9
Authors
0.00
FWCI
Topics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
9 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Carsten Flohr | — | — |
| 2 | Michael J. Cork | — | — |
| 3 | Michael R. Ardern‐Jones | — | |
| 4 | Lawrence F. Eichenfield | — | — |
| 5 | S. Barbarot | — | |
| 6 | Claire Feeney | — | — |
| 7 | Ricardo Rojo | — | — |
| 8 | Irina Lazariciu | — | — |
| 9 | John Nesnas | — |
Related Works
10Data: OpenAlex